Lindbrook Capital LLC Buys 96 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Lindbrook Capital LLC increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 85.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 209 shares of the company’s stock after purchasing an additional 96 shares during the period. Lindbrook Capital LLC’s holdings in Neurocrine Biosciences were worth $28,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of NBIX. Headinvest LLC bought a new position in shares of Neurocrine Biosciences in the third quarter worth $28,000. BluePath Capital Management LLC acquired a new stake in Neurocrine Biosciences in the third quarter valued at about $35,000. Sunbelt Securities Inc. boosted its stake in Neurocrine Biosciences by 34.3% in the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after buying an additional 83 shares in the last quarter. Fifth Third Bancorp boosted its stake in Neurocrine Biosciences by 51.3% in the third quarter. Fifth Third Bancorp now owns 622 shares of the company’s stock valued at $70,000 after buying an additional 211 shares in the last quarter. Finally, C M Bidwell & Associates Ltd. acquired a new stake in Neurocrine Biosciences in the third quarter valued at about $100,000. Institutional investors own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on NBIX shares. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Citigroup reduced their price objective on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a research note on Thursday, February 8th. JPMorgan Chase & Co. lifted their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Barclays lifted their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $150.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $142.38.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $135.99 on Friday. The company has a market cap of $13.53 billion, a P/E ratio of 56.19 and a beta of 0.25. The stock has a 50 day simple moving average of $136.63 and a two-hundred day simple moving average of $127.85. Neurocrine Biosciences, Inc. has a fifty-two week low of $89.04 and a fifty-two week high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.88 earnings per share. On average, research analysts predict that Neurocrine Biosciences, Inc. will post 4.83 earnings per share for the current year.

Insider Activity

In other news, insider Eric Benevich sold 75,000 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the completion of the sale, the insider now owns 40,778 shares in the company, valued at $5,683,637.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Eric Benevich sold 75,000 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the completion of the sale, the insider now owns 40,778 shares in the company, valued at $5,683,637.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eiry Roberts sold 1,457 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $140.79, for a total value of $205,131.03. Following the sale, the insider now owns 20,832 shares of the company’s stock, valued at approximately $2,932,937.28. The disclosure for this sale can be found here. Insiders sold a total of 186,994 shares of company stock worth $25,806,409 over the last quarter. 4.40% of the stock is currently owned by corporate insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.